Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Maria Gavriatopoulou and Ioannis Ntanasis-Stathopoulos.
Maria Gavriatopoulou
Connection Strength
2.854
Ioannis Ntanasis-Stathopoulos
  1. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clin Exp Med. 2021 Jul 20.
    View in: PubMed
    Score: 0.239
  2. SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. Hemasphere. 2021 Mar; 5(3):e547.
    View in: PubMed
    Score: 0.232
  3. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021 May; 21(2):167-179.
    View in: PubMed
    Score: 0.228
  4. Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020 Nov; 20(4):493-506.
    View in: PubMed
    Score: 0.224
  5. Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leuk Lymphoma. 2019 03; 60(3):619-628.
    View in: PubMed
    Score: 0.201
  6. Multidisciplinary management of complicated small bowel adenocarcinoma on the ground of Crohn's disease. J BUON. 2019 Jan-Feb; 24(1):408-409.
    View in: PubMed
    Score: 0.201
  7. How I treat rituximab refractory patients with WM. Oncotarget. 2018 Dec 07; 9(96):36824-36825.
    View in: PubMed
    Score: 0.200
  8. Rare manifestations of extramedullary myeloma: testicular plasmacytomas. Leuk Lymphoma. 2018 08; 59(8):2002-2004.
    View in: PubMed
    Score: 0.186
  9. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018 01 25; 131(4):464-467.
    View in: PubMed
    Score: 0.186
  10. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021 08 02; 11(8):138.
    View in: PubMed
    Score: 0.060
  11. Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells. 2021 07 30; 10(8).
    View in: PubMed
    Score: 0.060
  12. High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines (Basel). 2021 Jul 01; 9(7).
    View in: PubMed
    Score: 0.060
  13. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021 07 01; 137(26):3674-3676.
    View in: PubMed
    Score: 0.060
  14. Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. J Infect. 2021 07; 83(1):1-16.
    View in: PubMed
    Score: 0.059
  15. Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms. 2021 Mar 06; 9(3).
    View in: PubMed
    Score: 0.058
  16. COVID-19: time to flatten the infodemic curve. Clin Exp Med. 2021 May; 21(2):161-165.
    View in: PubMed
    Score: 0.058
  17. Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses. 2020 12 25; 13(1).
    View in: PubMed
    Score: 0.058
  18. Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies. Leuk Lymphoma. 2019 08; 60(8):1978-1990.
    View in: PubMed
    Score: 0.051
  19. Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Ann Hematol. 2019 Jun; 98(6):1427-1434.
    View in: PubMed
    Score: 0.051
  20. Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. Int J Cancer. 2019 07 15; 145(2):559-568.
    View in: PubMed
    Score: 0.050
  21. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid. 2018 Dec; 25(4):234-241.
    View in: PubMed
    Score: 0.050
  22. Micronutrient Intake and Risk of Hematological Malignancies in Adults: A Systematic Review and Meta-analysis of Cohort Studies. Nutr Cancer. 2018 Aug-Sep; 70(6):821-839.
    View in: PubMed
    Score: 0.049
  23. Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. Blood Cancer J. 2018 05 11; 8(5):42.
    View in: PubMed
    Score: 0.048
  24. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2018 06; 18(6):431-437.
    View in: PubMed
    Score: 0.048
  25. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018 01 12; 8(1):7.
    View in: PubMed
    Score: 0.047
  26. Clear cell "sugar tumor" of the lung: Diagnostic features of a rare pulmonary tumor. Respir Med Case Rep. 2018; 23:52-54.
    View in: PubMed
    Score: 0.047
  27. Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases. Leuk Lymphoma. 2018 04; 59(4):983-987.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.